MapQuant DX signature evaluates 98 genes in a molecular diagnostic test for estrogen receptor positive, grade II breast cancer patients to measure tumor proliferation, the risk of metastasis and response to chemotherapy [41]. This evidence concerns the gene ESR1 and breast carcinoma.